Clinical trial NCT06206694: Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients
Official title: Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malnutrition
Oxidative Stress
Keywords: YKL-40
nutrition status
hemodialysis patients
inflammation
Lead sponsor: Tungs' Taichung Metroharbour Hospital
Sponsor class: OTHER
First posted: 2024-01-16
Enrollment: 226
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.

Brief summary: Background

YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients

Methods

We plan to recruit 400 prevalent HD patients. Their baseline serum YKL-40 levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, and nutritional indices will be measured.

Detailed description: Study Design and Patients

Patients This is a prospective observational study. The patients will be recruited from HD patients at dialysis units of Tungs Taichung Metroharbour Hospital, which is an outpatient facility. The study inclusion criteria of participants are those maintain on HD therapy for at least 3 months prior to enrollment and being in stable condition without co-morbidities such as heart failure, infection, cirrhosis, respiratory disease, nephrotic syndrome, malignancy, chronic liver disease, or severe inflammation. None of the patients are receiving surgical operations or hospitalized in recent 3 months. In this study, written informed consent will be obtained from all participants. The study protocol will be send to the institutional review board of Tungs Taichung Metroharbour Hospital for approval. The study will be registered to the ClinicalTrial. Gov. Registry and will fully adhered to the guidelines of the Declaration of Helsinki

Methodology

Laboratory measurements Blood samples will be collected before dialysis session. Serum biochemistry such as albumin, urea nitrogen, uric acid, creatinine, total cholesterol, triacylglycerol levels, total ion binding capacity (TIBC), 25-hydroxyvitamin D, hemoglobin, and white blood count are measured employing standard laboratory techniques with the use of an automatic analyzer. Serum prealbumin and high-sensitivity C-reactive protein (hs-CRP) are quantified by nephelometry. YKL-40 and interleukin-6 (IL-6) were quantified by a double-sided sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R\&D Systems ; Minneapolis, MN, USA).

Fasting glucose levels were measured, after overnight fast and classified according to the American Diabetes Association (ADA) standards \[29\]. In addition, the serum insulin level, and hemoglobin A1c level are measured. The assessment of insulin resistance is done using the HOMA-IR index \[30\]: HOMA - IR = fasting glucose (in mmol/l) × fasting insulin (in µU/ml) / 22.5 Serum insulin, vaspin, and adiponectin level is measured by a commercially available ELISA kit following the manufacturer's instructions. Markers of oxidative stress such as total antioxidant capacity \[TAC\]), serum advanced oxidation protein products (AOPP) and serum CML (a component of AGEs) will also be measured.

Evaluation of nutritional status and body composition

Anthropometric measures including body weight, body mass index (BMI), waist and hip circumference, mid-arm circumference, and the waist-hip ratio (WHR) will be obtained. BMI is determined by the standard formula and further categorized according to the Asia Pacific version of the WHO classification \[31-32\]. According to this system, BMI\<18 kg/m2 is underweight; 18 to 22.9 is normal weight; 23 to 24.9 is marginal overweight; 25 to 29.9 is overweight; and greater than 30 is obesity \[27, 28\]. Lastly, the conicity index at baseline is determined to quantify the degree of central obesity \[33\].

Patients' nutrition status is determined by their serum albumin and pre-albumin levels, Subjective Global Assessment (SGA) score, normalized protein nitrogen appearance (NPNA), and fat-free edema-free body mass (FEBM). The 4-item 7-point SGA scoring system is employed \[34\]. NPNA was calculated using the modifed Bergstrom's formula \[35\]. FEBM was calculated using the creatinine kinetic method following the Forbes and Brunining formula \[36\], and reported as a percentage of their ideal body weight.

We use the multi-frequency bio-impedance spectroscopy device (Body Composition Monitor, Fresenius Medical Care, Germany) as described previously \[36, 37\]. In this study, the data on lean tissue mass (LTM), adipose tissue mass (ATM), the volume of over-hydration (OH), and the extracellular-tointracellular volume (E: I) ratio will be analyzed.

Statistical analysis All variables were analysed using a Kolmogorov-Smirnov test to classify them as normally or non-normally distributed. Values are given as mean \[standard deviation (SD)\] or median (IQR). Univariate analysis is performed to examine the relationships between YKL-40 and other parameters employing Spearman's rank correlation coefficient. Multivariate analysis is performed for parameters showing significant differences. Potential confounding factors for increased YKL-40 are assessed using a multiple regression analysis model based on general variables, inflammatory markers and correlations with malnutrition (p\<0.10). Two-sided P values of \<0.05 are considered to be statistically significant in all analyses. All statistical analyses were performed with the SPSS 23.0 statistical package (SPSS, Chicago, IL, USA). A p-value \<0.05 is considered statistically significant.

Eligibility criteria: Inclusion Criteria:

* Both sexes aged 20 years or over
* Received stable hemodialysis at least 3 months.
* Written informed consent.

Exclusion Criteria:

* heart failure
* infection
* cirrhosis
* respiratory disease
* nephrotic syndrome
* malignancy
* chronic liver disease
* severe inflammation
* None of the patients are receiving surgical operations or hospitalized in recent 3 months.

Primary outcomes:
measure: Analysis of biomarkers of YKL40
timeFrame: 1 years
measure: Evaluation of nutritional status and body composition
timeFrame: 1 years
Secondary outcomes:
measure: Analysis of biomarkers of IL-6
timeFrame: 1 years
measure: vaspin
timeFrame: 1 years
measure: insulin
timeFrame: 1 years
measure: adiponectin
timeFrame: 1 years
measure: total antioxidant capacity
timeFrame: 1 years
measure: AOPP
timeFrame: 1 years
measure: Nε-Carboxymethyllysine (CML)
timeFrame: 1 years
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Tungs' Taichung MetroHarbour Hospital
Study officials:
affiliation: Tungs' Taichung Metroharbour Hospital
name: Paik Seong Lim, PhD
role: PRINCIPAL_INVESTIGATOR
References: